IMU Biosciences

IMU Biosciences is a London-based biotechnology company that applies artificial intelligence to systems-level immune profiling. Its stated purpose is to decode the immune system at high resolution and scale, with the aim of improving the understanding, diagnosis and treatment of disease. The company was founded on research conducted at King's College London and the Francis Crick Institute and describes itself as a science-led organisation.

Its core technology is the HD Immunology platform, a multi-omic offering that combines massively scalable immune phenotyping with proprietary real-time AI analytics. According to the company, the platform measures more than 100 million immune data points from a single 2ml blood sample and resolves 2,500 discrete immune cell subsets in real time, producing immune insights that can be applied at clinical scale. Alongside the platform, IMU has built what it describes as the world's largest immune dataset: more than 25,000 deeply characterised samples spanning health and disease, which the company positions as a universal standard for immune measurement.

The work is applied across precision medicine and immunology, including immuno-oncology, haematopoietic stem cell transplantation, solid organ transplantation and immune-mediated diseases. IMU Biosciences partners with pharmaceutical and biotech companies on these programmes. The website is https://imubiosciences.com/.